Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: Synergism upon coapplication

American Journal of Respiratory Cell and Molecular Biology

Volumn 25, Issue 2, 2001, Pages 219-225

  Schermuly, R T ^a   Weissmann, N ^a   Enke, B ^a   Ghofrani, H A ^a   Forssmann, W G ^a   Grimminger, F ^a   Seeger, W ^a   Walmrath, D ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0034876188     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/ajrcmb.25.2.4256     Document Type: Article

References (45)

1. Isolation and structural analysis of "urodilatin," a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine
2. The endocrine heart and natriuretic peptides: Histochemistry, cell biology, and functional aspects of the renal urodilatin system
3. Renal endocrine, and hemodynamic interactions of atrial and brain natriuretic peptides in normal men
4. Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats: The ventricle is a major site of synthesis and secretion of brain natriuretic peptide
5. Molecular biology of the natriuretic peptides and their receptors
6. Atrial natriuretic peptide concentrations and pulmonary hemodynamics in patients with pulmonary artery hypertension
7. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension
8. Atrial natriuretic factor attenuates the pulmonary pressor response to hypoxia
9. Atrial natriuretic peptide attenuates the development of pulmonary hypertension in rats adapted to chronic hypoxia
10. Effects of natriuretic peptides and neutral endopeptidase 24.11 inhibition in isolated perfused rat lung
11. Atrial natriuretic factor in chronic obstructive lung diseases with pulmonary hypertension
12. Intravenously administered atrial natriuretic factor in patients with COPD
13. 1 in the adult respiratory distress syndrome: Benefit for pulmonary hypertension and cost for pulmonary gas exchange
14. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis
15. Brain natriuretic peptide inhibits hypoxic pulmonary hypertension in rats
16. Comparison of renal actions of urodilatin and atrial natriuretic peptide
17. Significance of prophylactic urodilatin (INN: Ularitide) infusion for the prevention of acute renal failure in patients after heart transplantation
18. Urodilatin, a new therapy to prevent kidney failure after heart transplantation
19. Efficacy of prolonged infusion of urodilatin [ANP-(95-126)] in patients with congestive heart failure
20. Bronchodilating effects of natriuretic and vasorelaxant peptides compared to salbutamol in asthmatics
21. Urodilatin (ularitide, INN): A potent bronchodilator in asthmatic subjects
22. Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension
23. Ultrasonic nebulization for efficient delivery of surfactant in a model of acute lung injury: Impact on gas exchange
24. On-line laser-photometric monitoring of aerosol deposition in ventilated rabbit lungs
25. Efficacy of inhaled prostanoids in experimental pulmonary hypertension
26. Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension
27. Effect of urodilatin on platelet-activating factor-induced bronchoconstriction, vasoconstriction and edema formation in isolated rat lung
28. The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11
29. Pharmacokinetics of ANF and urodilatin during cANF receptor blockade and neutral endopeptidase inhibition
30. Urodilatin (CDD/ANP-95-126) is not biologically inactivated by a peptidase from dog kidney cortex membranes in contrast to atrial nariuretic peptide/cardiodilatin (alpha-hANP/CDD-99-126)
31. Recent progress in understanding the hormonal regulation of phosphodiesterases
32. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms
33. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families
34. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents
35. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors
36. Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats
37. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta
38. Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase
39. Aerosolized prostacyclin and iloprost in primary pulmonary hypertension
40. Aerosolized prostacyclin reduces pulmonary artery pressure and improves gas exchange in the adult respiratory distress syndrome (ARDS)
41. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome
42. Subthreshold doses of specific phosphodiesterase type 3 and 4-inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange
43. The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide
44. Selective pulmonary vasodilation induced by aerosolized zaprinast
45. Effect of i.v. dipyridamole on cerebral blood flow, blood pressure, plasma adenosine and cAMP levels in rabbits